Among them, glucagon-like peptide-1 (GLP-1), secreted from intestinal L-cells in response to nutrient ingestion, has attracted much attention because of its mimetics for the treatment of obesity (69), lowering glucose levels, and improving insulin sensitivity in individuals with type 2 diabetes and in animal models (70). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.